Subcommittee I on the free movement of goods – Medicinal products – List of marketing authorisations granted by the EEA EFTA States for the second half of 2024
Date: 2025-07-03
Institutions: Standing Committee of the EFTA States
Subjects: EFTA countries, European Economic Area, free movement of goods, market approval, medicinal product, withdrawal from the market








C_202503652EN.000101.fmx.xml












Official Journal of the European Union


EN
C series













C/2025/3652


3.7.2025






Subcommittee I on the free movement of goods
Medicinal products – List of marketing authorisations granted by the EEA EFTA States for the second half of 2024
(C/2025/3652)
(Text with EEA relevance)

With reference to EEA Joint Committee Decision No 74/1999 of 28 May 1999, the EEA Joint Committee is invited to note the following lists concerning marketing authorisations for medicinal products for the period 
            1 July – 31 December 2024
         , at their meeting on 14.3.2025:






Annex I


List of new marketing authorisations




Annex II


List of renewed marketing authorisations




Annex III


List of extended marketing authorisations




Annex IV


List of withdrawn marketing authorisations




Annex V


List of suspended marketing authorisations








ANNEX I
List of new marketing authorisations
The following marketing authorisations have been granted in the EEA EFTA States during the period 
            1 July – 31 December 2024:









EU-Number


Product


Country


Date of authorisation




EU/1/24/1880


ABSIMKY


Liechtenstein


31.12.2024




EU/1/24/1837


ADZYNMA


Iceland


2.9.2024




EU/1/24/1837


ADZYNMA


Liechtenstein


31.8.2024




EU/1/24/1837


ADZYNMA


Norway


7.8.2024




EU/1/24/1867


Afqlir


Iceland


11.12.2024




EU/1/24/1867


Afqlir


Liechtenstein


30.11.2024




EU/1/24/1867


Afqlir


Norway


18.11.2024




EU/1/24/1840


AKANTIOR


Iceland


12.9.2024




EU/1/24/1840


AKANTIOR


Liechtenstein


31.8.2024




EU/1/24/1840


AKANTIOR


Norway


27.8.2024




EU/2/24/306


Alcort


Iceland


1.7.2024




EU/1/24/1881


Alhemo


Liechtenstein


31.12.2024




EU/1/24/1824


Altuvoct


Iceland


15.8.2024




EU/1/24/1851


Anzupgo


Iceland


15.10.2024




EU/1/24/1851


Anzupgo


Liechtenstein


30.9.2024




EU/1/24/1851


Anzupgo


Norway


9.10.2024




EU/1/24/1835


Apexelsin


Iceland


26.8.2024




EU/1/24/1835


Apexelsin


Liechtenstein


31.7.2024




EU/1/24/1835


Apexelsin


Norway


29.7.2024




EU/2/24/323


ArthriCox


Iceland


12.11.2024




EU/2/24/323


ArthriCox


Liechtenstein


31.10.2024




EU/1/24/1834


Avzivi


Iceland


26.8.2024




EU/1/24/1834


Avzivi


Liechtenstein


31.7.2024




EU/1/24/1834


Avzivi


Norway


2.8.2024




EU/1/24/1847


Axitinib Accord


Iceland


15.10.2024




EU/1/24/1847


Axitinib Accord


Liechtenstein


30.9.2024




EU/1/24/1847


Axitinib Accord


Norway


9.10.2024




EU/1/24/1841


Balversa


Iceland


12.9.2024




EU/1/24/1841


Balversa


Liechtenstein


31.8.2024




EU/1/24/1841


Balversa


Norway


26.8.2024




EU/2/24/325


BRAVECTO TriUNO


Liechtenstein


30.11.2024




EU/2/24/325


BRAVECTO TriUNO


Norway


6.12.2024




EU/1/24/1809


Buprenorphine Neuraxpharm


Liechtenstein


31.12.2024




EU/2/24/328


Carprofen Orion


Liechtenstein


31.12.2024




EU/1/24/1833


Cejemly


Iceland


30.8.2024




EU/1/24/1833


Cejemly


Liechtenstein


31.7.2024




EU/1/24/1833


Cejemly


Norway


29.7.2024




EU/2/24/321


Cepeloron


Iceland


11.10.2024




EU/2/24/321


Cepeloron


Liechtenstein


30.9.2024




EU/2/24/321


Cepeloron


Norway


19.9.2024




EU/2/24/320


Cevac Salmune ETI K


Iceland


12.9.2024




EU/2/24/320


Cevac Salmune ETI K


Liechtenstein


31.8.2024




EU/2/24/320


Cevac Salmune ETI K


Norway


30.8.2024




EU/2/24/322


Cirbloc M Hyo


Iceland


12.11.2024




EU/2/24/322


Cirbloc M Hyo


Liechtenstein


31.10.2024




EU/2/24/322


Cirbloc M Hyo


Norway


5.11.2024




EU/1/24/1839


Dasatinib Accord Healthcare


Iceland


26.8.2024




EU/1/24/1839


Dasatinib Accord Healthcare


Liechtenstein


31.7.2024




EU/1/24/1839


Dasatinib Accord Healthcare


Norway


6.8.2024




EU/2/24/318


Divence IBR Marker Live


Iceland


30.8.2024




EU/2/24/318


Divence IBR Marker Live


Liechtenstein


31.8.2024




EU/2/24/318


Divence Ibr Marker Live


Norway


21.8.2024




EU/2/24/307


Divence Penta


Iceland


29.7.2024




EU/2/24/310


Divence Tetra


Iceland


14.8.2024




EU/2/24/327


DuOtic


Iceland


12.12.2024




EU/2/24/327


DuOtic


Liechtenstein


30.11.2024




EU/2/24/327


DuOtic


Norway


27.11.2024




EU/1/24/1838


DURVEQTIX


Iceland


30.8.2024




EU/1/24/1838


DURVEQTIX


Liechtenstein


31.7.2024




EU/1/24/1838


DURVEQTIX


Norway


30.7.2024




EU/1/24/1858


Eksunbi


Iceland


17.9.2024




EU/1/24/1858


Eksunbi


Liechtenstein


30.9.2024




EU/1/24/1858


Eksunbi


Norway


20.9.2024




EU/1/24/1866


ELAHERE


Iceland


11.12.2024




EU/1/24/1866


ELAHERE


Liechtenstein


30.11.2024




EU/1/24/1866


ELAHERE


Norway


19.11.2024




EU/1/24/1869


Eltrombopag Viatris


Liechtenstein


31.12.2024




EU/1/24/1869


Eltrombopag Viatris


Norway


18.12.2024




EU/1/24/1842


Enzalutamide Viatris


Iceland


12.9.2024




EU/1/24/1842


Enzalutamide Viatris


Liechtenstein


31.8.2024




EU/1/24/1842


Enzalutamide Viatris


Norway


27.8.2024




EU/1/24/1819


Eribulin Baxter


Iceland


16.8.2024




EU/1/24/1819


Eribulin Baxter


Norway


15.7.2024




EU/1/24/1846


EURneffy


Iceland


12.9.2024




EU/1/24/1846


EURneffy


Liechtenstein


31.8.2024




EU/1/24/1846


EURneffy


Norway


27.8.2024




EU/1/24/1878


Fluad


Iceland


12.12.2024




EU/1/24/1878


Fluad


Liechtenstein


30.11.2024




EU/1/24/1878


Fluad


Norway


3.12.2024




EU/1/24/1879


Flucelvax


Iceland


12.12.2024




EU/1/24/1879


Flucelvax


Liechtenstein


30.11.2024




EU/1/24/1879


Flucelvax


Norway


3.12.2024




EU/1/24/1816


Fluenz


Iceland


15.8.2024




EU/1/24/1827


Fruzaqla


Iceland


16.8.2024




EU/1/24/1862


Fymskina


Iceland


16.10.2024




EU/1/24/1862


Fymskina


Liechtenstein


30.9.2024




EU/1/24/1862


Fymskina


Norway


9.10.2024




EU/1/24/1836


GalliaPharm


Iceland


30.8.2024




EU/1/24/1836


GalliaPharm


Liechtenstein


31.8.2024




EU/1/24/1836


GalliaPharm


Norway


8.8.2024




EU/1/24/1874


Hympavzi


Iceland


16.12.2024




EU/1/24/1874


Hympavzi


Liechtenstein


30.11.2024




EU/1/24/1874


Hympavzi


Norway


22.11.2024




EU/1/24/1855


Iqirvo


Iceland


15.10.2024




EU/1/24/1855


Iqirvo


Liechtenstein


30.9.2024




EU/1/24/1855


Iqirvo


Norway


8.10.2024




EU/1/24/1872


IMULDOSA


Liechtenstein


31.12.2024




EU/2/24/315


Innovax-ND-H5


Iceland


15.8.2024




EU/1/24/1861


Ituxredi


Iceland


14.10.2024




EU/1/24/1861


Ituxredi


Liechtenstein


30.9.2024




EU/1/24/1861


Ituxredi


Norway


9.10.2024




EU/1/24/1828


IXCHIQ


Iceland


29.8.2024




EU/1/24/1828


IXCHIQ


Norway


1.7.2024




EU/1/24/1854


KAYFANDA


Iceland


14.10.2024




EU/1/24/1854


KAYFANDA


Liechtenstein


30.9.2024




EU/1/24/1854


KAYFANDA


Norway


9.10.2024




EU/1/24/1818


JERAYGO


Iceland


16.8.2024




EU/1/24/1818


JERAYGO


Norway


1.7.2024




EU/2/24/308


Lexylan


Iceland


1.7.2024




EU/2/24/311


Lotimax


Iceland


29.7.2024




EU/1/24/1853


LOQTORZI


Iceland


14.10.2024




EU/1/24/1853


LOQTORZI


Liechtenstein


30.9.2024




EU/1/24/1853


LOQTORZI


Norway


9.10.2024




EU/1/24/1849


mRESVIA


Iceland


12.9.2024




EU/1/24/1849


mRESVIA


Liechtenstein


31.8.2024




EU/1/24/1849


mRESVIA


Norway


28.8.2024




EU/1/24/1845


Nilotinib Accord


Iceland


12.9.2024




EU/1/24/1845


Nilotinib Accord


Liechtenstein


31.8.2024




EU/1/24/1845


Nilotinib Accord


Norway


28.8.2024




EU/2/24/316


Nobilis Multriva RT+IBm+ND+EDS


Iceland


21.8.2024




EU/2/24/316


Nobilis Multriva RT+IBm+ND+EDS


Liechtenstein


31.7.2024




EU/2/24/317


Nobilis Multriva RT+IBm+ND+Gm+REOm


Iceland


29.8.2024




EU/2/24/317


Nobilis Multriva RT+IBm+ND+Gm+REOm


Liechtenstein


31.7.2024




EU/2/24/309


Nobilis Multriva RT+IBm+ND+Gm+REOm+EDS


Iceland


14.8.2024




EU/2/24/309


Nobilis Multriva RT+IBm+ND+Gm+REOm+EDS


Liechtenstein


31.7.2024




EU/1/24/1822


Obgemsa


Iceland


16.8.2024




EU/1/24/1822


Obgemsa


Norway


15.7.2024




EU/1/24/1865


Opuviz


Iceland


11.12.2024




EU/1/24/1865


Opuviz


Liechtenstein


30.11.2024




EU/1/24/1865


Opuviz


Norway


22.11.2024




EU/1/24/1843


Ordspono


Iceland


12.9.2024




EU/1/24/1843


Ordspono


Liechtenstein


31.8.2024




EU/1/24/1843


Ordspono


Norway


27.8.2024




EU/1/24/1863


Otulfi


Iceland


15.10.2024




EU/1/24/1863


Otulfi


Liechtenstein


30.9.2024




EU/1/24/1863


Otulfi


Norway


9.10.2024




EU/1/24/1871


Penbraya


Iceland


11.12.2024




EU/1/24/1871


Penbraya


Liechtenstein


30.11.2024




EU/1/24/1871


Penbraya


Norway


19.11.2024




EU/1/24/1848


Piasky


Iceland


13.9.2024




EU/1/24/1848


Piasky


Liechtenstein


31.8.2024




EU/1/24/1848


Piasky


Norway


28.8.2024




EU/1/24/1831


Pomalidomide Accord


Iceland


29.8.2024




EU/1/24/1831


Pomalidomide Accord


Liechtenstein


31.7.2024




EU/1/24/1831


Pomalidomide Accord


Norway


2.8.2024




EU/1/24/1832


Pomalidomide Krka


Iceland


29.8.2024




EU/1/24/1832


Pomalidomide Krka


Liechtenstein


31.7.2024




EU/1/24/1832


Pomalidomide Krka


Norway


6.8.2024




EU/1/24/1868


Pomalidomide Teva


Iceland


11.12.2024




EU/1/24/1868


Pomalidomide Teva


Liechtenstein


30.11.2024




EU/1/24/1868


Pomalidomide Teva


Norway


22.11.2024




EU/1/24/1830


Pomalidomide Zentiva


Iceland


29.8.2024




EU/1/24/1830


Pomalidomide Zentiva


Liechtenstein


31.7.2024




EU/1/24/1830


Pomalidomide Zentiva


Norway


29.7.2024




EU/2/24/319


Porcilis PCV M Hyo ID


Iceland


12.9.2024




EU/2/24/319


Porcilis PCV M Hyo ID


Liechtenstein


31.8.2024




EU/1/24/1860


Ranibizumab Midas


Iceland


11.10.2024




EU/1/24/1860


Ranibizumab Midas


Liechtenstein


30.9.2024




EU/1/24/1860


Ranibizumab Midas


Norway


9.10.2024




EU/2/24/314


Respivac TRT


Iceland


21.8.2024




EU/1/24/1844


Steqeyma


Iceland


12.9.2024




EU/1/24/1844


Steqeyma


Liechtenstein


31.8.2024




EU/1/24/1844


Steqeyma


Norway


28.8.2024




EU/1/24/1799


Tauvid


Iceland


13.9.2024




EU/1/24/1799


Tauvid


Liechtenstein


31.8.2024




EU/1/24/1799


Tauvid


Norway


28.8.2024




EU/1/24/1852


Theralugand


Iceland


12.12.2024




EU/1/24/1852


Theralugand


Liechtenstein


30.11.2024




EU/1/24/1852


Theralugand


Norway


3.12.2024




EU/1/24/1825


Tofidence


Iceland


16.8.2024




EU/1/24/1825


Tofidence


Norway


15.7.2024




EU/2/24/312


Trilocur


Iceland


15.8.2024




EU/2/24/313


Trilorale


Iceland


15.8.2024




EU/1/24/1820


Truqap


Iceland


15.8.2024




EU/1/24/1864


Tuznue


Iceland


11.10.2024




EU/1/24/1864


Tuznue


Liechtenstein


30.9.2024




EU/2/24/326


Vaxxon ND Clone


Iceland


12.12.2024




EU/2/24/326


Vaxxon ND Clone


Liechtenstein


30.11.2024




EU/2/24/326


Vaxxon ND Clone


Norway


10.12.2024




EU/1/24/1857


Vevizye


Iceland


11.10.2024




EU/1/24/1857


Vevizye


Liechtenstein


30.9.2024




EU/1/24/1857


Vevizye


Norway


9.10.2024




EU/1/24/1856


Vyloy


Iceland


11.10.2024




EU/1/24/1856


Vyloy


Liechtenstein


30.9.2024




EU/1/24/1856


Vyloy


Norway


8.10.2024




EU/1/24/1823


Wezenla


Iceland


21.8.2024




EU/1/24/1823


Wezenla


Norway


15.7.2024




EU/1/24/1850


Winrevair


Iceland


13.9.2024




EU/1/24/1850


Winrevair


Liechtenstein


31.8.2024




EU/1/24/1850


Winrevair


Norway


28.8.2024




EU/1/24/1859


Yuvanci


Iceland


16.10.2024




EU/1/24/1859


Yuvanci


Liechtenstein


30.9.2024




EU/1/24/1859


Yuvanci


Norway


8.10.2024




EU/1/24/1829


Zegalogue


Iceland


29.8.2024




EU/1/24/1829


Zegalogue


Liechtenstein


31.7.2024




EU/1/24/1829


Zegalogue


Norway


29.7.2024









ANNEX II
List of renewed marketing authorisations
The following marketing authorisations have been renewed in the EEA EFTA States during the period 
            1 July – 31 December 2024:









EU-Number


Product


Country


Date of authorisation




EU/1/21/1539


Abecma


Iceland


20.8.2024




EU/1/19/1415


Amsparity


Iceland


16.10.2024




EU/1/19/1415


Amsparity


Liechtenstein


30.9.2024




EU/1/19/1415


Amsparity


Norway


9.10.2024




EU/1/19/1398


Arsenic Trioxide Accord


Iceland


16.10.2024




EU/1/19/1398


Arsenic Trioxide Accord


Liechtenstein


30.9.2024




EU/1/19/1398


Arsenic Trioxide Accord


Norway


14.10.2024




EU/1/20/1473


AYVAKYT


Iceland


28.8.2024




EU/1/20/1473


AYVAKYT


Liechtenstein


31.7.2024




EU/1/20/1473


AYVAKYT


Norway


7.8.2024




EU/1/19/1413


Azacitidine Accord


Liechtenstein


31.12.2024




EU/1/19/1416


Azacitidine Betapharm


Liechtenstein


31.12.2024




EU/1/19/1416


Azacitidine Betapharm


Norway


16.12.2024




EU/1/20/1426


Azacitidine Mylan


Liechtenstein


30.11.2024




EU/1/20/1426


Azacitidine Mylan


Norway


6.12.2024




EU/1/19/1406


Baqsimi


Iceland


11.9.2024




EU/1/19/1406


Baqsimi


Liechtenstein


31.8.2024




EU/1/19/1406


Baqsimi


Norway


28.8.2024




EU/1/19/1417


Beovu


Iceland


16.10.2024




EU/1/19/1417


Beovu


Liechtenstein


30.9.2024




EU/1/19/1417


Beovu


Norway


9.10.2024




EU/1/19/1397


Bortezomib Fresenius Kabi


Liechtenstein


31.10.2024




EU/1/19/1397


Bortezomib Fresenius Kabi


Norway


21.10.2024




EU/1/22/1648


Carvykti


Iceland


20.8.2024




EU/1/19/1409


Cegfila


Iceland


11.9.2024




EU/1/19/1409


Cegfila


Liechtenstein


31.8.2024




EU/1/19/1409


Cegfila


Norway


27.8.2024




EU/1/20/1429


Cinacalcet Accordpharma


Liechtenstein


31.12.2024




EU/2/21/281


CircoMax


Liechtenstein


31.8.2024




EU/2/21/281


CircoMax


Norway


26.8.2024




EU/1/19/1395


Clopidogrel/Acetylsalicylic acid Viatris


Iceland


11.9.2024




EU/1/19/1395


Clopidogrel/Acetylsalicylic acid Viatris


Liechtenstein


31.8.2024




EU/1/19/1395


Clopidogrel/Acetylsalicylic acid Viatris


Norway


22.8.2024




EU/1/23/1742


Columvi


Iceland


30.8.2024




EU/1/23/1742


Columvi


Liechtenstein


31.5.2024 (1)





EU/1/19/1365


Cufence


Iceland


18.7.2024




EU/1/19/1412


Deferasirox Accord


Liechtenstein


30.11.2024




EU/1/19/1412


Deferasirox Accord


Norway


3.12.2024




EU/1/19/1386


Deferasirox Mylan


Iceland


28.8.2024




EU/1/19/1386


Deferasirox Mylan


Liechtenstein


31.7.2024




EU/1/19/1386


Deferasirox Mylan


Norway


29.7.2024




EU/1/19/1418


Dexmedetomidine Accord


Iceland


11.12.2024




EU/1/19/1418


Dexmedetomidine Accord


Liechtenstein


31.10.2024




EU/1/19/1418


Dexmedetomidine Accord


Norway


30.10.2024




EU/1/23/1770


ELREXFIO


Liechtenstein


30.11.2024




EU/1/20/1508


Enhertu


Iceland


12.11.2024




EU/1/20/1508


Enhertu


Liechtenstein


31.10.2024




EU/1/20/1508


Enhertu


Norway


14.11.2024




EU/1/19/1389


Epidyolex


Iceland


28.8.2024




EU/1/19/1389


Epidyolex


Liechtenstein


31.7.2024




EU/1/19/1389


Epidyolex


Norway


2.8.2024




EU/1/19/1411


Evenity


Iceland


10.9.2024




EU/1/19/1411


Evenity


Liechtenstein


31.8.2024




EU/1/19/1411


Evenity


Norway


28.8.2024




EU/1/20/1433


Fluad Tetra


Liechtenstein


31.12.2024




EU/1/21/1555


GAVRETO


Iceland


16.10.2024




EU/1/21/1555


GAVRETO


Liechtenstein


30.9.2024




EU/1/21/1555


GAVRETO


Norway


18.10.2024




EU/1/19/1384


Giapreza


Iceland


18.7.2024




EU/1/20/1428


Givlaari


Liechtenstein


30.11.2024




EU/1/20/1428


Givlaari


Norway


22.11.2024




EU/1/19/1375


Grasustek


Iceland


19.7.2024




EU/1/22/1715


Hemgenix


Liechtenstein


31.12.2024




EU/1/22/1715


Hemgenix


Norway


16.12.2024




EU/2/18/226


HorStem


Liechtenstein


31.7.2024




EU/1/20/1471


Idefirix


Iceland


28.8.2024




EU/1/20/1471


Idefirix


Liechtenstein


31.7.2024




EU/1/20/1471


Idefirix


Norway


26.8.2024




EU/1/19/1390


Inbrija


Iceland


19.8.2024




EU/1/19/1407


Isturisa


Iceland


12.11.2024




EU/1/19/1407


Isturisa


Liechtenstein


31.10.2024




EU/1/19/1407


Isturisa


Norway


21.10.2024




EU/1/23/1738


Jaypirca


Iceland


28.8.2024




EU/1/23/1738


Jaypirca


Liechtenstein


31.8.2024




EU/1/23/1738


Jaypirca


Norway


22.8.2024




EU/1/22/1657


Kinpeygo


Iceland


28.8.2024




EU/1/22/1657


Kinpeygo


Norway


19.8.2024




EU/1/21/1552


Koselugo


Iceland


16.7.2024




EU/1/23/1744


Krazati


Liechtenstein


30.11.2024




EU/1/23/1744


Krazati


Norway


18.12.2024




EU/1/19/1383


Lacosamide UCB


Iceland


16.7.2024




EU/1/21/1603


Lumykras


Liechtenstein


30.11.2024




EU/1/21/1603


Lumykras


Norway


26.11.2024




EU/1/22/1649


Lunsumio


Iceland


16.7.2024




EU/1/19/1381


LysaKare


Iceland


18.7.2024




EU/1/23/1741


Lytgobi


Iceland


18.7.2024




EU/1/19/1414


Mayzent


Iceland


16.10.2024




EU/1/19/1414


Mayzent


Liechtenstein


30.9.2024




EU/1/19/1414


Mayzent


Norway


9.10.2024




EU/1/21/1570


Minjuvi


Iceland


20.8.2024




EU/1/21/1570


Minjuvi


Liechtenstein


31.7.2024




EU/2/19/247


Mirataz


Liechtenstein


31.8.2024




EU/1/20/1425


Nilemdo


Liechtenstein


30.11.2024




EU/1/20/1432


NUBEQA


Iceland


12.11.2024




EU/1/20/1432


NUBEQA


Liechtenstein


31.10.2024




EU/1/20/1432


NUBEQA


Norway


29.10.2024




EU/1/19/1364


Nuceiva


Iceland


18.7.2024




EU/1/20/1424


Nustendi


Liechtenstein


30.11.2024




EU/1/20/1424


Nustendi


Norway


3.12.2024




EU/1/21/1618


Nuvaxovid


Iceland


10.10.2024




EU/1/21/1618


Nuvaxovid


Norway


16.9.2024




EU/1/19/1362


PALYNZIQ


Iceland


18.7.2024




EU/1/16/1089


Pandemic influenza vaccine H5N1 AstraZeneca


Iceland


18.7.2024




EU/1/19/1379


Posaconazole Accord


Iceland


16.7.2024




EU/1/19/1393


Quofenix


Iceland


10.9.2024




EU/1/19/1393


Quofenix


Liechtenstein


31.8.2024




EU/1/19/1393


Quofenix


Norway


28.8.2024




EU/1/19/1420


Recarbrio


Iceland


16.10.2024




EU/1/19/1420


Recarbrio


Liechtenstein


30.9.2024




EU/1/19/1420


Recarbrio


Norway


9.10.2024




EU/1/19/1400


Rhokiinsa


Iceland


24.9.2024




EU/1/19/1400


Rhokiinsa


Liechtenstein


30.9.2024




EU/1/19/1400


Rhokiinsa


Norway


18.9.2024




EU/1/19/1404


RINVOQ


Iceland


16.10.2024




EU/1/19/1404


RINVOQ


Liechtenstein


30.9.2024




EU/1/19/1404


RINVOQ


Norway


9.10.2024




EU/1/22/1668


Roctavian


Iceland


10.9.2024




EU/1/22/1668


Roctavian


Liechtenstein


31.8.2024




EU/1/20/1460


Rozlytrek


Iceland


18.7.2024




EU/1/20/1431


Ruxience


Liechtenstein


30.11.2024




EU/1/20/1431


Ruxience


Norway


5.12.2024




EU/1/20/1430


Rybelsus


Liechtenstein


30.11.2024




EU/1/20/1430


Rybelsus


Norway


3.12.2024




EU/1/21/1594


Rybrevant


Iceland


20.8.2024




EU/1/21/1594


Rybrevant


Liechtenstein


30.6.2024 (2)





EU/1/14/978


Senshio


Iceland


16.10.2024




EU/1/14/978


Senshio


Liechtenstein


31.10.2024




EU/1/14/978


Senshio


Norway


8.10.2024




EU/1/13/901


Sirturo


Iceland


20.8.2024




EU/1/13/901


Sirturo


Liechtenstein


30.6.2024 (3)





EU/1/22/1688


Spevigo


Liechtenstein


30.11.2024




EU/1/22/1688


Spevigo


Norway


10.10.2024 (4)

19.11.2024




EU/1/19/1410


Spravato


Iceland


10.9.2024




EU/1/19/1410


Spravato


Liechtenstein


31.8.2024




EU/1/19/1410


Spravato


Norway


28.8.2024




EU/1/23/1748


TALVEY


Iceland


19.8.2024




EU/1/19/1377


Talzenna


Iceland


16.7.2024




EU/1/19/1405


TAVLESSE


Liechtenstein


30.11.2024




EU/1/19/1405


TAVLESSE


Norway


19.11.2024




EU/1/22/1675


Tecvayli


Iceland


19.8.2024




EU/1/23/1759


Tepkinly


Iceland


20.8.2024




EU/1/23/1759


Tepkinly


Liechtenstein


31.7.2024




EU/1/23/1759


Tepkinly


Norway


1.8.2024




EU/1/19/1394


Tigecycline Accord


Liechtenstein


30.11.2024




EU/1/19/1419


Trepulmix


Liechtenstein


31.12.2024




EU/1/19/1419


Trepulmix


Norway


20.12.2024




EU/1/19/1371


ULTOMIRIS


Iceland


18.7.2024




EU/1/19/1385


VITRAKVI


Iceland


22.7.2024




EU/1/19/1385


VITRAKVI


Liechtenstein


31.7.2024




EU/1/19/1385


VITRAKVI


Norway


29.7.2024




EU/1/19/1399


Xospata


Iceland


20.8.2024




EU/1/19/1399


Xospata


Norway


10.7.2024




EU/1/19/1366


Xromi


Iceland


18.7.2024




EU/1/14/938


Zydelig


Iceland


20.8.2024




EU/1/14/938


Zydelig


Norway


1.7.2024




EU/1/22/1695


Zynlonta


Liechtenstein


30.11.2024




EU/1/22/1695


Zynlonta


Norway


27.11.2024






(1)  Authorisation was unintentionally omitted from the list for the 1st half of 2024.

(2)  Authorisation was unintentionally omitted from the list for the 1st half of 2024.

(3)  Authorisation was unintentionally omitted from the list for the 1st half of 2024.

(4)  The authorisation was unintentionally delayed and applied retroactively for 2024. With the authorisation dated 19.11.2024, the authorisation is now renewed.





ANNEX III
List of extended marketing authorisations
The following marketing authorisations have been extended in the EEA EFTA States during the period 
            1 July – 31 December 2024:









EU-Number


Product


Country


Date of authorisation




EU/1/12/809/019-020


Betmiga


Iceland


11.9.2024




EU/1/12/809/019-020


Betmiga


Norway


28.8.2024




EU/1/21/1575/009-012


Bimzelx


Iceland


2.9.2024




EU/1/21/1575/009-012


Bimzelx


Norway


7.8.2024




EU/1/14/974/004


Cerdelga


Norway


16.12.2024




EU/1/15/1036/003


Cresemba


Iceland


11.9.2024




EU/1/15/1036/003


Cresemba


Norway


27.8.2024




EU/1/20/1528/037-042


Comirnaty KP 2


Norway


2.10.2024




EU/1/11/736/002


EDURANT


Iceland


17.10.2024




EU/1/11/736/002


EDURANT


NORWAY


9.10.2024




EU/1/11/691/016-019


Eliquis


Iceland


2.9.2024




EU/1/11/691/016-019


Eliquis


Norway


6.8.2024




EU/1/18/1315/003-004


Mektovi


Iceland


19.8.2024




EU/1/10/614/005-006


Menveo


Iceland


10.12.2024




EU/1/10/614/005-006


Menveo


Norway


3.12.2024




EU/1/17/1231/003


Ocrevus


Iceland


19.8.2024




EU/1/17/1231/003


Ocrevus


Norway


22.7.2024




EU/1/13/893/004


Opsumit


Norway


4.12.2024




EU/1/13/893/004


Opsumit


Iceland


17.10.2024




EU/1/17/1209/043-050


Reagila


Norway


26.8.2024




EU/1/20/1460/003


Rozlytrek


Iceland


19.8.2024




EU/1/20/1460/003


Rozlytrek


Norway


1.7.2024




EU/1/20/1430/016-030


Rybelsus


Norway


7.8.2024




EU/1/19/1361/007


Skyrizi


Iceland


2.9.2024




EU/1/12/793/005-007


XALKORI


Iceland


11.9.2024









ANNEX IV
List of withdrawn marketing authorisations
The following marketing authorisations have been withdrawn in the EEA EFTA States during the period 
            1 July – 31 December 2024:









EU-Number


Product


Country


Date of withdrawal




EU/1/17/1261


Alofisel


Liechtenstein


13.12.2024




EU/1/17/1261


Alofisel


Norway


18.12.2024




EU/1/09/559


Clopidogrel Taw Pharma


Iceland


11.11.2024




EU/1/09/559


Clopidogrel Taw Pharma


Liechtenstein


24.10.2024




EU/1/09/559


Clopidogrel Taw Pharma


Norway


24.10.2024




EU/1/12/750


Esmya


Iceland


27.8.2024




EU/1/12/750


Esmya


Liechtenstein


18.7.2024




EU/1/12/750


Esmya


Norway


13.8.2024




EU/1/08/473


Evicel


Iceland


21.8.2024




EU/1/08/473


Evicel


Liechtenstein


5.7.2024




EU/1/08/473


Evicel


Norway


13.8.2024




EU/1/08/454


Extavia


Liechtenstein


25.11.2024




EU/1/08/454


Extavia


Norway


25.11.2024




EU/1/14/983


Exviera


Iceland


16.10.2024




EU/1/14/983


Exviera


Liechtenstein


25.9.2024




EU/1/14/983


Exviera


Norway


16.10.2024




EU/2/96/002


Fevaxyn Pentofel


Iceland


11.11.2024




EU/2/96/002


Fevaxyn Pentofel


Liechtenstein


4.10.2024




EU/2/96/002


Fevaxyn Pentofel


Norway


13.11.2024




EU/1/21/1555


GAVRETO


Liechtenstein


24.10.2024




EU/1/21/1555


GAVRETO


Norway


27.11.2024




EU/1/18/1321


Gefitinib Mylan


Iceland


16.10.2024




EU/1/18/1321


Gefitinib Mylan


Liechtenstein


27.9.2024




EU/1/18/1321


Gefitinib Mylan


Norway


17.10.2024




EU/1/20/1525


JCOVDEN


Iceland


28.8.2024




EU/1/20/1525


JCOVDEN


Liechtenstein


26.7.2024




EU/1/20/1525


JCOVDEN


Norway


7.8.2024




EU/1/14/955


Lymphoseek


Iceland


21.8.2024




EU/1/14/955


Lymphoseek


Liechtenstein


30.6.2024 (1)





EU/1/14/955


Lymphoseek


Norway


12.8.2024




EU/1/18/1283


Pemetrexed Krka


Iceland


21.8.2024




EU/1/18/1283


Pemetrexed Krka


Norway


12.8.2024




EU/1/15/1037


Pemetrexed Sandoz


Iceland


11.11.2024




EU/1/15/1037


Pemetrexed Sandoz


Liechtenstein


9.10.2024




EU/1/15/1037


Pemetrexed Sandoz


Norway


13.11.2024




EU/1/22/1641


PreHevbri


Liechtenstein


25.11.2024




EU/1/22/1641


PreHevbri


Norway


6.12.2024




EU/1/13/826


Memantine LEK


Iceland


23.9.2024




EU/1/13/826


Memantine LEK


Liechtenstein


6.9.2024




EU/1/13/826


Memantine LEK


Norway


6.9.2024




EU/1/18/1290


Nityr


Iceland


21.8.2024




EU/1/18/1290


Nityr


Norway


12.8.2024




EU/1/20/1485


NYXTHRACIS


Iceland


28.8.2024




EU/1/20/1485


NYXTHRACIS


Liechtenstein


2.8.2024




EU/1/20/1485


NYXTHRACIS


Norway


8.8.2024




EU/2/98/009


Suvaxyn Aujeszky 783 + O/W


Iceland


11.11.2024




EU/2/98/009


Suvaxyn Aujeszky 783 + O/W


Liechtenstein


4.10.2024




EU/2/98/009


Suvaxyn Aujeszky 783 + O/W


Norway


13.11.2024




EU/1/11/719


Telmisartan Teva Pharma


Iceland


19.7.2024




EU/1/24/1797


Tizveni


Iceland


21.8.2024




EU/1/24/1797


Tizveni


Liechtenstein


5.7.2024




EU/1/24/1797


Tizveni


Norway


13.8.2024




EU/1/14/982


Viekirax


Iceland


16.10.2024




EU/1/14/982


Viekirax


Liechtenstein


25.9.2024




EU/1/14/982


Viekirax


Norway


17.10.2024




EU/1/03/264


Zevalin


Iceland


2.9.2024




EU/1/03/264


Zevalin


Liechtenstein


31.01.2024 (2)





EU/1/12/800


Zoledronic acid Hospira


Norway


1.8.2024






(1)  Authorisation was unintentionally omitted from the list for the 1st half of 2024.

(2)  Authorisation was unintentionally omitted from the list for the 1st half of 2024.





ANNEX V
List of suspended marketing authorisations
The following marketing authorisations have been suspended in the EEA EFTA States during the period 
            1 July – 31 December 2024:









EU-Number


Product


Country


Date of suspension




EU/1/21/1622


Oxbryta


Iceland


17.10.2024




EU/1/21/1622


Oxbryta


Norway


9.10.2024




EU/2/12/145


Kexxtone


Iceland


19.7.2024







ELI: http://data.europa.eu/eli/C/2025/3652/oj
ISSN 1977-091X (electronic edition)